Search research articles
Contact Us
Filters
Showing results (171-180 of 181) with videos related to
Page
of 19
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
December 26, 2025
Enhancing Radiotherapy Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131
Andrea C Lo, Sarah A Milgrom, Raymond Mailhot Vega, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 16, 2015
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Neeta Pandit-Taskar, Joseph A O'Donoghue, Jeremy C Durack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2021
High-Specific-Activity-<sup>131</sup>I-MIBG versus <sup>177</sup>Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma
Abhishek Jha, David Taïeb, Jorge A Carrasquillo, et al.
Cancer Chemotherapy and Pharmacology
|
January 26, 2017
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
Ghassan K Abou-Alfa, Chia-Jui Yen, Chih-Hung Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2023
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Steven B Maron, Walid Chatila, Henry Walch, et al.
JCO Oncology Advances
|
May 7, 2025
ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results
Emily K Slotkin, Audrey Mauguen, Filemon S Dela Cruz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2024
Randomized Phase III SIERRA Trial of <sup>131</sup>I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 19, 2015
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies
Vincent J Picozzi, Ramesh K Ramanathan, Maeve A Lowery, et al.
Journal for Immunotherapy of Cancer
|
March 27, 2026
CD8 PET imaging with [<sup>89</sup>Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study
Michael A Postow, Peter D Zang, Sumanta K Pal, et al.
Cancer Discovery
|
November 23, 2018
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Francisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 181) with videos related to
Sort By:
Page
of 19
International Journal of Radiation Oncology, Biology, Physics
|
December 26, 2025
Enhancing Radiotherapy Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131
Andrea C Lo, Sarah A Milgrom, Raymond Mailhot Vega, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 16, 2015
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Neeta Pandit-Taskar, Joseph A O'Donoghue, Jeremy C Durack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2021
High-Specific-Activity-<sup>131</sup>I-MIBG versus <sup>177</sup>Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma
Abhishek Jha, David Taïeb, Jorge A Carrasquillo, et al.
Cancer Chemotherapy and Pharmacology
|
January 26, 2017
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
Ghassan K Abou-Alfa, Chia-Jui Yen, Chih-Hung Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2023
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Steven B Maron, Walid Chatila, Henry Walch, et al.
JCO Oncology Advances
|
May 7, 2025
ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results
Emily K Slotkin, Audrey Mauguen, Filemon S Dela Cruz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2024
Randomized Phase III SIERRA Trial of <sup>131</sup>I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 19, 2015
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies
Vincent J Picozzi, Ramesh K Ramanathan, Maeve A Lowery, et al.
Journal for Immunotherapy of Cancer
|
March 27, 2026
CD8 PET imaging with [<sup>89</sup>Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study
Michael A Postow, Peter D Zang, Sumanta K Pal, et al.
Cancer Discovery
|
November 23, 2018
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Francisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.
Page
of 19